Life sciences firm LabCorp has launched the new UltraQual Multiplex PCR Assay in the US for the detection of viruses in donated blood plasma, following the US Food and Drug Administration (FDA) approval.

Developed by the National Genetics Institute (NGI) laboratory, the test is designed to simultaneously identify hepatitis C virus (HCV), human immunodeficiency virus (HIV) 1 and 2, and hepatitis B virus (HBV) in a single sample.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“These plasma-derived therapies, known as biologics, replace missing or deficient proteins in a patient’s plasma to treat various well-defined medical conditions.”

When combined with NGI’s process to enhance testing throughput, UltraQual is said to offer improved turnaround time and value.

The assay is intended to aid biopharmaceutical companies that manufacture plasma-derived therapies in assessing the safety and availability of their medicines.

These plasma-derived therapies, known as biologics, replace missing or deficient proteins in a patient’s plasma to treat various well-defined medical conditions.

LabCorp Diagnostics chief scientific officer Marcia Eisenberg said: “This next-generation technology offers the international biopharmaceutical industry a differentiated solution to improve plasma donor collection programmes and the manufacturing of plasma protein therapies for a variety of life-threatening conditions including bleeding, immune, cardio/pulmonary and neurological disorders.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In March this year, LabCorp’s Covance Drug Development unit launched an immunology and immunotoxicology (I&I) unit focussed on catering to global biologic drug development needs.

The I&I unit, Covance’s expanded laboratory footprint, and LabCorp Diagnostics’ boost to its biologic therapeutic drug monitoring tests range are expected to support the company’s strategy to develop and commercialise new services for biologics market.